Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Incidental SARS-CoV-2-related findings in asymptomatic ...
pubmed.ncbi.nlm.nih.gov › 32444898
1 Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. Ian.alberts@insel.ch. ... Betacoronavirus Coronavirus ...
Author: Ian Alberts, Bernd Vollnberg, Christos Sachpekidis, Christos Sachpekidis, Clemens Mingels, Sabine We...
Cited by: 5
Incidental SARS-CoV-2-related findings in asymptomatic patients in [ 18 F]-FDG-PET/CT-potential insights
Ian Alberts 1, Bernd Vollnberg 2, Christos Sachpekidis 2 3, Clemens Mingels 2, Sabine Weidner 2, Ali Afshar-Oromieh 2, Axel Rominger 2
Affiliations collapse
Affiliations
1Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. Ian.alberts@insel.ch.
2Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
3Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Heidelberg, Germany.
https://pubmed.ncbi.nlm.nih.gov/32444898/
The impact of the COVID-19 pandemic on patients with chronic ...
pubmed.ncbi.nlm.nih.gov › 32343839
9 Department of Dermatology, Inselspital University Hospital of Bern, Bern, Switzerland. 10 Dermatology Unit, ... Betacoronavirus / immunology*
Author: P. Gisondi, P. Facheris, P. Dapavo, S. Piaserico, A. Conti, L. Naldi, S. Cazzaniga, S. Cazzaniga, P....
Cited by: 64
Publish Year: 2020
https://pubmed.ncbi.nlm.nih.gov/32343839/
Cross presentation of antigens of recombinant overlapping peptides to optimise vaccines against tumour and infectious diseases
We have developed a technology to producing overlapping peptides - bacterial expression of an amino acid sequence corresponding to overlapping peptide sequences spanning the length of a protein of interest interspersed with enzymatic cleavage sites. The recombinant product can then be broken down by the cleavage sites for enzymes present in human antigen presenting cells to have a therapeutic effect. The overlapping peptides made that way are called recombinant overlapping peptides (ROPs).
https://www.oncology.ox.ac.uk/study-with-us/dphil-phd-programme/2021-22_dphil-projects/cross_pres
«Work, work, and work harder»
With the life-saving drug CAL02, Combioxin SA is revolutionizing the field of severe infections such as pneumonia. Managing Director Samareh Azeredo da Silveira Lajaunias explains how the spin-off successfully transforms the invention made at the Institute of Anatomy, University of Bern, to a market-ready pharmaceutical product.
Our lead drug candidate, CAL02, is a first-in-class drug with a novel technology and proven safety for humans. CAL02’s patented technology deploys re-engineered liposomes – tiny fat beads – to capture and neutralize bacterial toxins called virulence effectors. Traditional treatments of infections wage chemical warfare, seeking to destroy the pathogens, most frequently after dangerous toxins have already been released, destroying cells, damaging vital organs, disabling the immune system, and they trigger a potentially fatal inflammatory response in the patient.
https://www.uniaktuell.unibe.ch/2021/work_work_and_work_harder/index_eng.html
Why SARS-CoV-2 Replicates Better in the Upper Respiratory Tract
Cell culture models show that temperature is a key factor in SARS-CoV-2 replication
April 2, 2021
UNIVERSITY OF BERN
"The detailed analysis of SARS-CoV-2 replication and the temperature-induced changes in the host innate immune defense mechanisms helps explain why SARS-CoV-2 replicates so well in the upper respiratory tract, and is perhaps why SARS-CoV-2 exhibits higher human-to-human transmissibility than SARS-CoV," Dijkman explains.
https://www.labmanager.com/news/why-sars-cov-2-replicates-better-in-the-upper-respiratory-tract-25587
https://www.unibe.ch/news/media_news/media_relations_e/media_releases/2021/media_releases_2021/why_sars_cov_2_replicates_better_in_the_upper_respiratory_tract/index_eng.html
Vaccination by inhalation
Delivering vaccines directly to the lungs can boost immune responses to respiratory infections or lung cancer, study finds.
Anne Trafton | MIT News Office
Publication Date: March 19, 2021
MIT researchers have developed a new vaccination strategy that can create an army of T cells that can protect mucosal surfaces such as the lungs.
https://news.mit.edu/2021/vaccination-inhalation-0319
PT-141 (Bremelanotide) Nasal Spray
10ml contains 10mg PT-141 Peptide
25ml contains 25mg PT-141 Peptide
PT141 is a peptide that increases the production of nitric oxide in the body, thus allowing the blood vessels to open up, increasing the blood flow to the penis, making it more significant, and thus enabling a man to have an erection that lasts for a more extended period.
Pt141 is used to improve sexual desire in men and increase erections. Pt141 is even considered to be “pumps” that can increase blood flow to the penis, allowing for better erections.
https://pharmalabglobal.com/product/pt-141-nasal-spray/
NLA Nasal Spray - Meda
Alternative Names: NCX-1510; Nitric oxide-releasing cetirizine liposomal - Orexo; NLA; NO-releasing cetirizine liposomal - Orexo; OX-NLA
Latest Information Update: 03 Jun 2015
https://adisinsight.springer.com/drugs/800020184
‘Smell therapy’ from Baylor doctors might be an on-the-nose treatment for COVID recovery
Bozz District
2 weeks ago
https://unibistrodc.com/smell-therapy-from-baylor-doctors-might-be-an-on-the-nose-treatment-for-covid-recovery.html
MilliporeSigma Supports Jenner Institute to Reach First Milestone in Covid-19 Vaccine Manufacturing
Recently developed manufacturing platform allows large-scale manufacturing
Joint team reduced process development time to two months from a year – a critical step to manufacturing Covid-19 vaccine at scale
“We have brought the future of vaccine manufacturing to the present,” says MilliporeSigma CEO Udit Batra
Burlington, Massachusetts, April 14, 2020— MilliporeSigma and The Jenner Institute today announced that The Jenner Institute has laid the foundation for large-scale production of its Covid-19 vaccine candidate, ChAdOx1 nCoV-19.
https://www.emdmillipore.com/US/en/20200413_185330
7,956,358.5
10 percent of the float
another 10
20 percent
:}
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160802053
Yes Sir, To you and yours my friends!! ALL LONGS!! HAPPY GOOD FRIDAY AND EASTER :)
mymx_10q - SEC
www.sec.gov › Archives › edgar
The total potential number of shares issuable of 668,933,362 at March 31, 2019 includes 639,833,362 potential issuable shares related to convertible loans and 29,100,000 potential issuable shares related to outstanding not expired options granted to employees.
https://www.sec.gov/Archives/edgar/data/927761/000165495420005539/mymx_10q.htm
Mymetics : Amendment to Quarterly Report (SEC Filing - 10-Q/A ...
www.marketscreener.com › quote › stock
Mar 23, 2021 · The total potential number of shares issuable of 720,431,036 at September 30, 2020 includes 694,681,036 potential issuable shares related to convertible loans, and 25,750,000 potential issuable shares related to outstanding stock options granted to employees.
https://www.marketscreener.com/quote/stock/MYMETICS-CORPORATION-120787303/news/Mymetics-nbsp-Amendment-to-Quarterly-Report-SEC-Filing-10-Q-A-32761766/
In "Uncanny similarity of unique inserts in the 2019-nCoV spike protein to HIV-1 gp120 and Gag", Indian researchers are baffled by segments of the virus's RNA that have no relation to other corona viruses like SARS, and instead appear to be closer to HIV. The virus even responds to treatment by HIV medications.
I allows thought early about covid was very close to HIV. I asked myself why the Gov. brought to people that were in that field HIV to deal with it. They are not telling the whole story here?
Need some clarification on this friend!! confused
I MISSED IT!! :)
NICE FIND FRIEND!! :)
Viewpoint
Operation Warp Speed: implications for global vaccine security
Author links open overlay panel
Lancet Commission on COVID-19 Vaccines and Therapeutics Task Force Members†
Author links open overlay panel Jerome H Kim Peter Hotez Carolina Batista Onder ErgonulJ Peter Figueroa Sarah Gilbert Mayda Gursel MazenHassanainGagandeepKangBhavnaLallHeidiLarsonDeniseNanicheTimothySheahanShmuelShohamAnneliesWilder-SmithNathalieStrub-Wourgaft Prashant Yadav Maria Elena Bottazzi
Available online 26 March 2021.
https://www.sciencedirect.com/science/article/pii/S2214109X21001406#!
That's 11,650,413 more if my math is right! If Kempers sold any share he needs to report that!! and the public float as well!!
NOT GOOD!! BAD DRUG!
Upper Airway Compromise
RAGWITEK can cause local reactions in the mouth or throat that could compromise the upper airway [see ADVERSE REACTIONS]. Consider discontinuation of RAGWITEK in patients who experience persistent and escalating adverse reactions in the mouth or throat.
Eosinophilic Esophagitis
Eosinophilic esophagitis has been reported in association with sublingual tablet immunotherapy [see CONTRAINDICATIONS]. Discontinue RAGWITEK and consider a diagnosis of eosinophilic esophagitis in patients who experience severe or persistent gastro-esophageal symptoms including dysphagia or chest pain.
Asthma
Subjects with asthma who participated in clinical trials had asthma of a severity that required, at most, a daily low dose of an inhaled corticosteroid. RAGWITEK has not been studied in subjects with moderate or severe asthma.
Withhold immunotherapy with RAGWITEK if the patient is experiencing an acute asthma exacerbation. Reevaluate patients who have recurrent asthma exacerbations and consider discontinuation of RAGWITEK.
Concomitant Allergen Immunotherapy
RAGWITEK has not been studied in subjects who are receiving concomitant allergen immunotherapy. Concomitant dosing with other allergen immunotherapy may increase the likelihood of local or systemic adverse reactions to either subcutaneous or sublingual allergen immunotherapy.
Oral Inflammation
Stop treatment with RAGWITEK to allow complete healing of the oral cavity in patients with oral inflammation (e.g., oral lichen planus, mouth ulcers, or thrush) or oral wounds, such as those following oral surgery or dental extraction.
Why SARS-CoV-2 replicates better in the upper respiratory tract
Date:
March 31, 2021
Source:
University of Bern
Summary:
Researchers have assessed virus growth and activation of the cellular defense mechanisms in the respiratory tract. They have shown that natural temperature differences that exist in the upper and lower respiratory tract have a profound influence on SARS-CoV-2 replication and subsequent innate immune activation in human cells. The findings can help to develop antiviral drugs and preventive measures.
A team of researchers from the Institute for Infectious Diseases (IFIK) at the University of Bern and the Federal Institute of Virology and Immunology (IVI) have assessed virus growth and activation of the cellular defense mechanisms in the respiratory tract. They have shown that natural temperature differences that exist in the upper and lower respiratory tract have a profound influence on SARS-CoV-2 replication and subsequent innate immune activation in human cells. The findings can help to develop antiviral drugs and preventive measures.
https://www.sciencedaily.com/releases/2021/03/210331114747.htm
https://www.archyde.com/bern-discovery-this-is-how-the-coronavirus-multiplies-in-the-airways/
If they use VIROSOMES in Malaria! They use in schistosomiasis! :)
(PDF) Praziquantel: Mechanisms of action, resistance and new ...
www.researchgate.net › publication › 23445973
Nevertheless, th e established safety pr o?le of virosomes. ... Chemotherapeutic measures have been the mainstay in the control of schistosomiasis. The use of praziquantel, a relatively safe and
https://www.researchgate.net/publication/23445973_Praziquantel_Mechanisms_of_action_resistance_and_new_derivatives_for_schistosomiasis
VERY NICE!! :) Baylor College of Medicine has extended its collaboration with MilliporeSigma to advance a manufacturing platform to accelerate the transition of its candidate into Phase I clinical trials.
https://bioprocessintl.com/bioprocess-insider/deal-making/covid-19-round-up-vaccine-capacity-ma-deals-and-task-orders/
Worldwide Industry for Allergy Immunotherapies to 2026 – Featuring Stallergenes Greer, HAL Allergy & DBV Technologies Among Others – ResearchAndMarkets.com
03/19/2021
Companies Mentioned
ALK-Abello A/S
Allergy Therapeutics
Stallergenes Greer
HAL Allergy Group
DBV Technologies
Merck Group
Aimmune Therapeutics
Circassia Pharmaceuticals
Anergis SA
Biomay AG
What Anergis SA?
Merck not in Allergy market?
https://www.financialbuzz.com/worldwide-industry-for-allergy-immunotherapies-to-2026-featuring-stallergenes-greer-hal-allergy-dbv-technologies-among-others-researchandmarkets-com/
Who pays all there Salaries? University of Bern!! :)
Over 100 fully vaccinated people contract COVID-19 in Washington state, officials say
Wed, March 31, 2021, 4:53 AM·2 min read
Over 100 people in Washington state have tested positive for COVID-19 more than two weeks after becoming fully vaccinated against the disease, officials said.
The Washington State Department of Health is investigating reports of the so-called breakthrough cases, which it said are expected with any vaccine.
Officials said the so-called breakthrough cases are expected with any vaccine.
https://abcnews.go.com/Health/100-fully-vaccinated-people-contract-covid-19-washington/story?id=76784838
Terilyn Gaither
Lead Scientist at Catalent Pharma Solutions
Raleigh, North Carolina, United States
Lead Scientist with Supervisor and Project Director Duties
Company Name Catalent Pharma Solutions
Dates Employed Oct 2017 – Present
Employment Duration3 yrs 6 mos
Location Morrisville, NC
Technologist -Infectious Disease
Company Name LabCorp
Dates Employed Sep 2002 – Dec 2013
Employment Duration11 yrs 4 mos
• Isolated and amplified viral DNA and RNA using manual and automated methods with
manufactured kits
• Performed qualitative and quantitative viral load test, and genotyping assays for Human
Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), and Hepatitis C Virus (HCV)
• Performed qPCR and RT-qPCR amplification to quantify HCV
• Used ELISA hybridization to quantify HIV-1 viral levels
• Sanger Sequenced cDNA using ABI 3700 and 3730 XL and analyzed with Sequencher
• Verified, approved and reported lab results on tests performed according to laboratory policies
• Participated in proficiency testing of unknown samples, and continued education programs to
keep current of developments in the field
• Maintained both company and industry specific documentation standards while complying with
HIPAA, CLIA, cGMP, and GCP/GLP regulations
https://www.linkedin.com/in/terilyn-gaither-b3aaa313/
Tao Wang
Senior Scientist. Manager at Catalent Pharma Solutions
Washington DC-Baltimore Area
Experience
Catalent Pharma Solutions
Senior Scientist, Manager
Company Name Catalent Pharma Solutions Full-time
Dates Employed Jan 2020 – Present
Employment Duration 1 yr 3 mos
Location Baltimore, Maryland, United States
Paragon Bioservices, Inc.
Total Duration4 yrs 10 mos
Title Senior Scientist, Supervisor
Full-time
Dates Employed Nov 2017 – Jan 2020
Employment Duration2 yrs 3 mos
Location Baltimore, Maryland, United States
Title Staff Scientist, Supervisor
Full-time
Dates Employed Nov 2016 – Nov 2017
Employment Duration1 yr 1 mo
Location Baltimore, Maryland, United States
TitleS taff Scientist
Dates Employed Apr 2015 – Nov 2016
Employment Duration1 yr 8 mos
Research Scientist
Company Name NIH
Dates Employed Jul 2010 – Oct 2012
Employment Duration2 yrs 4 mos
Recognition of HIV-1 broadly neutralizing antibody 2F5 at its CDR H3 region by MPER peptide in the context of liposome
• Chemically modified 2F5 F100bC with different maleimide derivatives.
• Discovered that more hydrophobic modifications of 2F5 F100bC at residue F100bC leads to better neutralization of the antibody.
• Interacted and communicated effectively with direct supervisor and peer scientists in multiple teams to lead the project.
• Gained in-depth knowledge on electron paramagnetic resonance (EPR).
Structures of rabbit HIV-1 non-neutralizing MPER antibodies
• Worked together with industrial company on producing rabbit and mouse HIV-1 antibodies.
• Solved crystal structure of three antibodies.
• Acted as the technical representative of three FPLC/AKTA instruments, a Nanodrop instrument, enzyme supplies, and antibody supplies.
Chemical modifications of broadly neutralizing HIV-1 antibodies VRC07 and 10E8 to enhance their potency and breadth for potential passive therapy
• Chemically modified VRC07_G54C and 10E8_S77C using series of maleimides and iodoacetamides.
• Enhanced potency and breadth of VRC07 and 10E8 by series of chemical modifications.
• Gained expertise in antibody purification, ELISA, antibody affinity measurement using Biacore Surface Plasmon Resonance (SPR).
https://www.linkedin.com/in/tao-wang-032a5ab/
From Last post Cont:
Fig-5: Principle of vaccines per to viral vectorsNicotiana benthamiana TransgenicFig-6: VPL Vaccine Platform purified plant (MEDICAGO and GSK) Fig-7: Principle of vaccines by Messenger RNAFigure 2: The Different steps development of a VaccineMaminiaina Olivier FridolinReferences:[1]- Lai C-C, Shih T-P, Ko W-C, Tang H-J, Hsueh P-R (2020) Severe acute respiratory coronavirus syndrome 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and epidemic The challenges. International journal of antimicrobial agents 55: 105924-105924.[2]- Balkhair AA (2020) COVID-19 Pandemic: A New Chapter in the History of Infectious Diseases. Oman medical journal 35: e123-e123.[3]- Krammer F (2020) SARS-CoV-2 vaccines in development. Nature 586: 516-527.[4]- Mohapatra PR, Mishra B, Behera B (2020) BCG vaccination induced protection from COVID-19. The Indian Journal of Tuberculosis.[5]- Maminiaina O F ('2020) Origin of the cytokinic storm with COVID-19 (SARS-CoV2); POSTER-2020-IMVAVET/FOFIFA-DRZVP[6]- Huang Z, Chen Q, Hjelm B, Arntzen C, Mason H (2009)A DNA replica system for rapid high-level production of virus-like particles in plants. Biotechnology and bioengineering 103: 706-714.[7]. Fabre ML, Arras PN, Masson T, Pidre ML, Romanowski V (2020) Baculovirus-Derived Vectors for Immunization and Therapeutic Applications. Emerging and Reemerging Viral Pathogens: 197-224.ConclusionVaccine research against COVID-19 mobilizes a large number of researchers (universities, research centre and laboratories) and the meansfrom the large pharmaceutical companies (Fig-11) that have beensubsidized by their respective states. So much so that the first and secondgenerations of these vaccine platforms, having already proven themselves in the past, at human beings, are still widely used by different laboratories. As we havenoted, some of them are looking to the future using the third nucleic acid-based generation. In addition, they use different generationsinnovation in vaccineology, particularly adjuvants: Oily,Squalene (forerunnersteroids), based on bacterial derivatives or artificial vesicleslipids including or not viral proteins such as Liposomes,LNPsYes Fat NanoParticles (Fig-12) and the virosomes.However, a vaccine alone would not be enough to survive the coronavirus epidemic. According to Tedros Adhanom Ghebreyesus WHO Director-G
(PDF) Les différentes plateformes vaccinales proposées contre ...
www.researchgate.net › publication › 348805472_Les
ou Lipide NanoParticules (Fig-12) et les virosomes. Cependant, un vaccin ne suffirait pas à lui tout seul ... PFIZER/BIONTECH (BioNTech BNT162 cov id-19 ) ont ét ...
https://www.researchgate.net/publication/348805472_Les_differentes_plateformes_vaccinales_proposees_contre_le_SRAS-COV2
A Triple Co-Culture Model of the Human Respiratory Tract to ...
journals.plos.org › plosone › article
Sep 29, 2016 · The respiratory tract with its ease of access, vast surface area and dense network of antigen-presenting cells (APCs) represents an ideal target for immune-modulation. Bio-mimetic nanocarriers such as virosomes may provide immunomodulatory properties to treat diseases such as allergic asthma. In our study we employed a triple co-culture model of epithelial cells, macrophages and dendritic ...
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0163539
Merck
International journal of pharmaceutics 2014-12-3
Establishment and first characterization of a sublingual epithelial and immune cell co-culture model.
Abstract
We describe here the establishment and first characterization of a co-culture model of human epithelial sublingual cells (HO-1-u-1 cell line) and human dendritic cells derived from human peripheral blood monocytes (PBMC). Cell culture conditions for HO-1-u-1 cells were optimized. First characterization of phenotypic features by electron microscopy and fluorescence imaging revealed resemblance to sublingual tissue specimen from healthy donors. Successful co-culturing of epithelial and dendritic cells (DCs) was confirmed by confocal laser scanning microscopy. Stimulation of HO-1-u1 cells alone and the epithelial/DC co-culture by incubation with liposomes, virosomes and influenza virus lead reproducibly to the release of inflammatory cytokine GM-CSF. This co-culture model may be suitable for elucidation of mechanisms involved in the immune response at the sublingual epithelium as well as for the evaluation of novel topical vaccines, potentially replacing cumbersome ex vivo and in vivo methods currently in place.
https://www.sigmaaldrich.com/catalog/papers/25448555
Hmmm! Asthma on a Chip-MERCK
New Data from Emulate’s Asthma-on-Chip Presented at American Thoracic Society Annual Meeting
Emulate, Inc. May 23, 2017
The data demonstrates new capabilities that recreate viral-induced exacerbations of asthma in vitro on the Small Airway Lung-Chip, a system that holds the potential to facilitate drug discovery and development for the treatment of severe asthma
BOSTON, Mass., May 23, 2017 — Emulate Inc. presented data today that shows expanded functionality in modeling viral infection on the Small Airway Lung-Chip. This advancement opens new opportunities for studying viral-induced exacerbations of asthma using a human-relevant system. The data demonstrates the capability to model human airway tissue on the Small Airway Lung-Chip and to reproduce infection with a virus in vitro — recreating viral-induced exacerbation commonly experienced by asthma patients. The studies in the Small Airway Lung-Chip were carried out as part of a collaborative project between Emulate and Merck, known as MSD outside the United States and Canada.
https://www.emulatebio.com/press/asthma-chip-ats-annual-meeting/
https://www.emulatebio.com/collaborations
Come on we know all about this with University of Bern and Mymetics Lung on a chip with VIROSOMES: Mymetics/ Anergis SA/ University of Bern / and Stallergenes: ASTHMA CURE!!!
NEW OPPORTUNITIES IN RECOMBINANT PROTEIN VACCINE MARKET 2021 GROWTH, SEGMENTATION Market Study Report Date: 2021-03-29
Competitive dashboard: Merck , GSK , Sanofi , Zoties , Elanco , Boehringer-Ingelheim , Indian Immunologicals , Plumbline Life Sciences , Novavax and Medicago
https://www.express-journal.com/recombinant-protein-vaccine-market-372112/
Global Recombinant Vaccines Market Revenue and Value Chain 2020-2026| Zion Market Research
03-30-2021 11:24 AM CET | Health & Medicine
Press release from: Zion Market Research
Global Recombinant Vaccines Market: Competitive Players
Pfizer, Merck, Sanofi Pasteur, Bayer, GlaxoSmithKline, Serum Institute of India, Abiomed, Johnson & Johnson, Emergent Bio Solutions, and Mitsubishi Tanabe Pharma.
https://www.openpr.com/news/2263391/global-recombinant-vaccines-market-revenue-and-value-chain
Upperton's CEO Richard Johnson will be presenting a scientific poster titled “Developing Cold Chain Independent Vaccines - Spray-drying of Virosomes to Produce Dry Powder Formulations” on Tuesday 6th November at #AAPS2018 #PharmSci360 #Vaccines #NasalDelivery
5:35 AM · Nov 1, 2018·TweetDeck
https://twitter.com/UppertonLtd/status/1057974284851662848/photo/1
How This Lung-On-A-Chip Could Help Asthma Patients Breathe Easier
www.fastcompany.com › 3055583 › how-this-lung-on-a
So far, Emulate has also teamed with Merck to develop an intestine-chip, to work on inflammatory diseases like irritable bowel syndrome. The startup is also developing other organ systems working
There’s been a tremendous focus over the last few years in trying to understand why current [asthma] therapies do not work for this disease population, both looking for new therapies and also trying to develop new models that mimic the kind of response people have when they are exacerbating,” says Michael Simon, principal scientist for immunology at the drug company, Merck.
https://www.fastcompany.com/3055583/how-this-lung-on-a-chip-could-help-asthma-patients-breathe-easier
I would say to Mr. Kemper's Has back your self in a corner! GET IT DONE!!
very right my friend!!
Mymetics Phase II Nasal
(PDF) New Technologies for Influenza Vaccines
www.researchgate.net › publication › 346761382_New
Altimmune Phase II Nasal [32] V ector—alphavirus. AlphaV ax Phase II IM [33] Microorganisms 2020, 8, 1745 4 of 20. T able 1. ... Mymetics Phase II Nasal [42] Dendritic cells. CEL-SCI Phase I IM [43]
https://www.researchgate.net/publication/346761382_New_Technologies_for_Influenza_Vaccines#pff
Little old But interesting!!
This work introduces VaxiPatch, a novel vaccination system comprised of subunit glycoprotein vaccine antigens, adjuvants and dermal delivery. For this study, rHA of influenza virus B/Colorado/06/2017 was incorporated into synthetic virosomes, and adjuvant liposomes were formed with QS-21 from Saponaria quillaja, with or without the synthetic TLR4 agonist 3D – (6-acyl) PHAD.
https://www.pharmaexcipients.com/transdermal/vaxipatch-vaccination-system/